Vladimir Putin signed a decree transforming Scientific Industrial Company Microgen into a joint stock company, transferring 100% of the shares to Rostec Corporation. This transfer must be completed within the next 18 months. The holding company Natsimbio, which will include Microgen, seeks to implement Russia’s import substitution policy in the field of medicine.
In the coming years, various measures will be introduced to develop the industrial infrastructure and modernize the production of Microgen. First of all, this is necessary to ensure the uninterrupted completion of state orders for the supply of vaccines and other medicines, implement the import substitution program in the pharmaceutical sector, and provide citizens with quality domestic medications.
In an unstable foreign policy and difficult epidemic situations, independence from imported drugs is even more important
NIKOLAI SEMENOV, CEO OF NATSIMBIO
“Today, in an unstable foreign policy and difficult epidemic situations, independence from imported drugs is even more important. This is especially true with regard to the production of immunobiological drugs and medicines for the treatment of infectious diseases,” said Nikolai Semenov, CEO of the National Immuno Biological Company (Natsimbio).
According to the head of Natsimbio, the introduction of Microgen into the holding company as the largest developer and manufacturer of medicines to treat infectious diseases is important for the company and for the pharmaceutical industry as a whole.
The efforts of the holding company will be carried out in five key market segments for the state procurement of drugs: vaccines aligning with the national immunization schedule, TB medicine, blood products and human plasma, drugs for the treatment of HIV and hepatitis, and innovative medicines.
National Immuno Biological Company is Rostec Corporation’s pharmaceutical holding for the development and production of immunobiological drugs. The main challenge facing the company is to ensure the sovereignty of Russia in the field of biological safety.
SIC Microgen was established in 2003 by merging state unitary enterprises producing on immunobiological drugs. It ranks among the top three Russian pharmaceutical companies and is the largest domestic producer of immunobiological drugs, including vaccines, serums, specific immunoglobulins, cultures, allergens, and probiotics. Microgen has the unique scientific and industrial activity of producing bacteriophages, which are safe antibacterial drugs that function as an effective alternative to antibiotics.